OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market
This document is hosted externally.
Unless the owner has removed it from the web, you can access the full document via its original URL:
https://ose-immuno.com/wp-content/uploads/2021/04/EN_210426_Veloxis_VF-1.pdfUnless the owner has removed it from the web, you can access the full document via its original URL:
See similar contracts (4)
Alternatively, you can try searching for similar contracts:
